SCHEMBL25065124

SCHEMBL25065124

Cc1n[nH]cc1-c1ccc(C(C)(C)C)c(O)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.37
ALOX15 P16050 5/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
MAPT P10636 3/20 0.37
CYP1A2 P05177 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ATP2A2 P16615 1/20 0.37
ATP2A3 Q93084 1/20 0.37
TSHR P16473 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
TYR P14679 2/20 0.34
CA2 P00918 2/20 0.34
POLB P06746 1/20 0.34
MEN1 O00255 5/20 0.33
RAB9A P51151 5/20 0.33
KMT2A Q03164 5/20 0.33
NPC1 O15118 4/20 0.33
TP53 P04637 3/20 0.33
LMNA P02545 3/20 0.33
CYP3A4 P08684 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30729456 1.00 ALDH1A1 (0.37) ALDH1A1ALOX15SMN1; SMN2MAPTCYP1A2
SCHEMBL26021960 0.82 CYP11B2 (0.34) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL22393902 0.81 PIK3CD (0.40) ALDH1A1ALOX15MAPTCYP1A2KDM4E
SCHEMBL22313716 0.78 APP (0.35) ALDH1A1ALOX15SMN1; SMN2MAPTKDM4E
SCHEMBL22214063 0.76 LMNA (0.46) ALDH1A1ALOX15CA2MEN1RAB9A
SCHEMBL21035191 0.74 ALDH1A1 (0.59) ALDH1A1ALOX15SMN1; SMN2MAPTCYP1A2
SCHEMBL24962104 0.74 TRPA1 (0.33) LMNATRPA1
SCHEMBL16261248 0.73 ALDH1A1 (0.33) ALDH1A1SMN1; SMN2TYRCA2POLB
SCHEMBL15889361 0.73 PIM1 (0.44) ALDH1A1ALOX15SMN1; SMN2MAPTCYP1A2
SCHEMBL2419516 0.73 MEN1 (0.40) SMN1; SMN2TDP1MEN1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230054781-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SF3B5 ALDH1A1 3964/4885ALOX15 677/4885SMN1; SMN2 124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.